Please Wait.....
Report
Global Non-Small Cell Lung Cancer Treatment Market Report and Forecast 2023-2031
Market Report I 2023-04-14 I 160 Pages I EMR Inc.
Global Non-Small Cell Lung Cancer Treatment Market Report and Forecast 2023-2031
Global Non-Small Cell Lung Cancer Treatment Market Outlook
The global non-small cell lung cancer treatment market size was estimated to be worth USD 17.8 billion in 2022. The market is likely to grow at a rate of 10% during the forecast period of 2023-2031. Driven by the growing demand for diagnostics and therapeutics, the market is anticipated to be worth USD 41.97 billion by 2031.
Non-Small Cell Lung Cancer Treatment Market: Introduction
The market is expected to grow significantly during the forecast period of 2023-2031, driven by the rising prevalence of non-small cell lung cancer (NSCLC) across the globe and the increasing investment in research and development activities. NSCLC is a type of lung cancer that accounts for approximately 85% of all lung cancer cases. The disease is caused by the uncontrolled growth of abnormal cells in the lung tissue, which can spread to other parts of the body. There are various treatment options available for NSCLC, including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.
The report by Expert Market Research provides a comprehensive analysis of the non-small cell lung cancer treatment market, including market size, growth, and trends. NSCLC is a type of lung cancer that affects the epithelial cells of the lungs. The disease is responsible for a significant proportion of lung cancer-related deaths globally. The report covers the market for NSCLC treatment, including drugs and therapies used for the treatment of NSCLC.
Non-Small Cell Lung Cancer Epidemiology
Non-small cell lung cancer is a leading cause of cancer-related deaths worldwide, with an estimated 1.8 million new cases diagnosed annually. The disease is more common in men than women and is strongly associated with smoking. Other risk factors include exposure to environmental pollutants and a family history of lung cancer. NSCLC is typically diagnosed in patients aged 65 or older, although it can occur at any age.
The five-year survival rate for NSCLC depends on the stage of the disease at diagnosis, with early-stage disease having a better prognosis than advanced-stage disease. Overall, the five-year survival rate for NSCLC is approximately 24%, although this varies widely depending on the stage of the disease.
The incidence of NSCLC varies widely across the world, with the highest rates seen in developed countries with high rates of smoking, such as the United States, Europe, and Japan. In contrast, the incidence of NSCLC is lower in developing countries, although it is increasing as smoking rates and environmental pollution levels rise.
As the global population continues to age and smoking rates remain high in many parts of the world, the prevalence of NSCLC is expected to continue to rise in the coming years. This is expected to drive the growth of the NSCLC treatment market, as healthcare providers seek new and innovative therapies to manage this deadly disease.
NON SMALL CELL LUNG CANCER TREATMENT Market Segmentations
The market can be categorised into type, treatment type, drug class, therapy type, distribution channel, and end user.
Market Breakup by Type
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Others
Market Breakup by Treatment Type
- Immunotherapy
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Others
Market Breakup by Drug Class
- Alkylating Agents
- Epidermal Growth Factor Receptor Blocker
- Antimetabolites
- Mitotic Inhibitors
- Multi-kinase Inhibitors
- Others
Market Breakup by Therapy Type
- Single Drug Therapy
- Combination Therapy
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Non Small Cell Lung Cancer Treatment Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Non-Small Cell Lung Cancer Treatment Market Scenario
The market is expected to experience significant growth during the forecast period of 2023-2031. The key drivers of the market include the increasing prevalence of NSCLC, growing awareness about the disease, and advancements in medical technology. In addition, the rising demand for personalized medicine and targeted therapies is expected to further boost the market growth.
North America dominates the NSCLC treatment market, followed by Europe and Asia Pacific. The high prevalence of NSCLC in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for NSCLC treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.
The market for NSCLC treatment can be categorized into various segments, including drug type, therapy type, and distribution channel. The most used drug types for NSCLC treatment include chemotherapy, immunotherapy, targeted therapy, and others. The therapy type segment can be further categorized into surgery, radiation therapy, and others. In terms of distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Key Players in the Global Non-Small Cell Lung Cancer Treatment Market
The report gives an in-depth analysis of the key players involved in the Non-Small Cell Lung Cancer Treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- Eli Lilly and Company
- Celgene Corporation (Bristol-Myers Squibb Company)
- Pfizer Inc.
- AstraZeneca
- Sanofi
- Novartis AG
- Astellas Pharma Inc.
- Boehringer Ingelheim International GmbH
- Merck & Co. Inc.
- Takeda Pharmaceutical Company Limited
- Clovis Oncology
- Johnson & Johnson Services, Inc.
- Teva Pharmaceutical Industries Ltd.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Non-Small Cell Lung Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Non-Small Cell Lung Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Non-Small Cell Lung Cancer Epidemiology (2016-2031)
5.3 Europe Non-Small Cell Lung Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Non-Small Cell Lung Cancer Epidemiology (2016-2031)
5.5 Latin America Non-Small Cell Lung Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Non-Small Cell Lung Cancer Epidemiology (2016-2031)
6 Global Non-Small Cell Lung Cancer Treatment Market Overview
6.1 Global Non-Small Cell Lung Cancer Treatment Market Historical Value (2016-2022)
6.2 Global Non-Small Cell Lung Cancer Treatment Market Forecast Value (2023-2031)
7 Global Non-Small Cell Lung Cancer Treatment Market Landscape
7.1 Non-Small Cell Lung Cancer: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Non-Small Cell Lung Cancer: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Drug Class
7.2.4 Analysis by Therapy Type
7.2.5 Analysis by Distribution Channel
7.2.6 Analysis by End User
8 Non-Small Cell Lung Cancer : Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Non-Small Cell Lung Cancer Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Non-Small Cell Lung Cancer Treatment Market Segmentation
11.1 Global Non-Small Cell Lung Cancer Treatment Market by Type
11.1.1 Market Overview
11.1.2 Adenocarcinoma
11.1.3 Squamous Cell Carcinoma
11.1.4 Large Cell Carcinoma
11.1.5 Others
11.2 Global Non-Small Cell Lung Cancer Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.2 Immunotherapy
11.2.3 Chemotherapy
11.2.4 Radiation Therapy
11.2.5 Targeted Therapy
11.2.6 Others
11.3 Global Non-Small Cell Lung Cancer Treatment Market by Drug Class
11.3.1 Market Overview
11.3.2 Alkylating Agents
11.3.3 Epidermal Growth Factor Receptor Blocker
11.3.4 Antimetabolites
11.3.5 Mitotic Inhibitors
11.3.6 Multi-kinase Inhibitors
11.3.7 Others
11.4 Global Non-Small Cell Lung Cancer Treatment Market by Therapy Type
11.4.1 Market Overview
11.4.2 Single Drug Therapy
11.4.3 Combination Therapy
11.5 Global Non-Small Cell Lung Cancer Treatment Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacies
11.5.3 Retail Pharmacies
11.5.4 Online
11.5.5 Others
11.6 Global Non-Small Cell Lung Cancer Treatment Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Homecare
11.6.4 Specialty Clinics
11.6.5 Others
11.7 Global Non-Small Cell Lung Cancer Treatment Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Non-Small Cell Lung Cancer Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Non-Small Cell Lung Cancer Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Non-Small Cell Lung Cancer Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Non-Small Cell Lung Cancer Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Non-Small Cell Lung Cancer Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Genentech, Inc. (F. Hoffmann-La Roche Ltd)
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Eli Lilly and Company
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Celgene Corporation (Bristol-Myers Squibb Company)
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Pfizer Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 AstraZeneca
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Sanofi
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Astellas Pharma Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Boehringer Ingelheim International GmbH
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Merck & Co. Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Takeda Pharmaceutical Company Limited
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Clovis Oncology
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Johnson & Johnson Services, Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Teva Pharmaceutical Industries Ltd.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
24 Non-Small Cell Lung Cancer Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security